Pembrolizumab vs Tislelizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Pembrolizumab

Marketed by Merck & Co.

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT02142738 · Phase 3 · completed

The trial randomized 305 participants to pembrolizumab or active platinum-based chemotherapy, but treatment was open-label rather than double-blinded. Its radiographically assessed primary endpoint, 6-month progression-free survival, was met: 62.1% with pembrolizumab versus 50.3% with chemotherapy, with p<0.001 and a hazard ratio of 0.50 (95% CI 0.37–0.68).

Next expected readout: November 2026 · NCT06545331 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) Rate at Month 6: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2) (met)

Result source: NCT02142738

Tislelizumab

Marketed by BeOne Medicines and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03358875 · Phase 3 · completed

The 805-participant trial was randomized and actively controlled with docetaxel, and its co-primary clinical endpoint of overall survival was met in both the full population and the PD-L1-positive subgroup. However, treatment assignment was not blinded, so despite the large sample and statistically significant survival results, the evidence is rated moderate rather than strong.

Next expected readout: November 2026 · NCT06704620 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPembrolizumabTislelizumab
PFS, median8.8 vs 4.9+3.9 vs placebon 410NCT02578680
17 other results
7.6 vs 5.5vs Paclitaxel + Carboplatinn 120NCT03594747
5 other results
OS, median15.9 vs 11.3+4.6 vs placebon 278NCT02775435
15 other results
26.1 vs 19.4vs Paclitaxel + Carboplatinn 120NCT03594747
1 other result
ORR47.6% vs 18.9%+28.7 vs placebon 410NCT02578680
14 other results
  • 57.9% vs 38.4% n 278 · Phase 3 · secondary NCT02775435
  • 29% vs 27.1% n 245 · Phase 3 · secondary NCT03515837
  • 39.1% vs 32% wk 191 · n 299 · Phase 3 · secondary NCT02220894
  • 33.2% vs 28.9% wk 191 · n 413 · Phase 3 · secondary NCT02220894
  • 27.2% vs 26.5% wk 191 · n 637 · Phase 3 · secondary NCT02220894
  • 44.8% vs 27.8% n 154 · Phase 3 · secondary NCT02142738
  • 22.7% vs 14.3% n 185 · Phase 3 · secondary NCT03976375
  • 22.7% vs 12.5% n 185 · Phase 3 · secondary NCT03976375
  • 28.1% vs 7.1% n 114 · Phase 3 · secondary NCT02864394
  • 20.7% vs 5.7% n 213 · Phase 3 · secondary NCT02864394
  • 5.4% vs 11.1% n 37 · Phase 2 · primary NCT04165096
  • 71.4% n 112 · Phase 2 · primary NCT03631784
  • 75.5% n 102 · Phase 2 · primary NCT03631784
  • 22% vs 28% n 69 · Phase 2 · secondary NCT03971474
74.2% vs 47.9%vs Paclitaxel + Carboplatinn 120NCT03594747
3 other results
  • 73.9% vs 47.9% n 119 · Phase 3 · secondary NCT03594747
  • 70% vs 49.6% n 120 · Phase 3 · secondary NCT03594747
  • 78.2% vs 49.6% n 119 · Phase 3 · secondary NCT03594747
Duration of response, median11.2 vs 7.8+3.4 vs placebon 195NCT02578680
8 other results
8.4 vs 4.3vs Paclitaxel + Carboplatinn 89NCT03594747
3 other results

PFS, median

Pembrolizumab
8.8 vs 4.9+3.9 vs placebon 410NCT02578680
17 other results
Tislelizumab
7.6 vs 5.5vs Paclitaxel + Carboplatinn 120NCT03594747
5 other results

OS, median

Pembrolizumab
15.9 vs 11.3+4.6 vs placebon 278NCT02775435
15 other results
Tislelizumab
26.1 vs 19.4vs Paclitaxel + Carboplatinn 120NCT03594747
1 other result

ORR

Pembrolizumab
47.6% vs 18.9%+28.7 vs placebon 410NCT02578680
14 other results
  • 57.9% vs 38.4% n 278 · Phase 3 · secondary NCT02775435
  • 29% vs 27.1% n 245 · Phase 3 · secondary NCT03515837
  • 39.1% vs 32% wk 191 · n 299 · Phase 3 · secondary NCT02220894
  • 33.2% vs 28.9% wk 191 · n 413 · Phase 3 · secondary NCT02220894
  • 27.2% vs 26.5% wk 191 · n 637 · Phase 3 · secondary NCT02220894
  • 44.8% vs 27.8% n 154 · Phase 3 · secondary NCT02142738
  • 22.7% vs 14.3% n 185 · Phase 3 · secondary NCT03976375
  • 22.7% vs 12.5% n 185 · Phase 3 · secondary NCT03976375
  • 28.1% vs 7.1% n 114 · Phase 3 · secondary NCT02864394
  • 20.7% vs 5.7% n 213 · Phase 3 · secondary NCT02864394
  • 5.4% vs 11.1% n 37 · Phase 2 · primary NCT04165096
  • 71.4% n 112 · Phase 2 · primary NCT03631784
  • 75.5% n 102 · Phase 2 · primary NCT03631784
  • 22% vs 28% n 69 · Phase 2 · secondary NCT03971474
Tislelizumab
74.2% vs 47.9%vs Paclitaxel + Carboplatinn 120NCT03594747
3 other results
  • 73.9% vs 47.9% n 119 · Phase 3 · secondary NCT03594747
  • 70% vs 49.6% n 120 · Phase 3 · secondary NCT03594747
  • 78.2% vs 49.6% n 119 · Phase 3 · secondary NCT03594747

Duration of response, median

Pembrolizumab
11.2 vs 7.8+3.4 vs placebon 195NCT02578680
8 other results
Tislelizumab
8.4 vs 4.3vs Paclitaxel + Carboplatinn 89NCT03594747
3 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Pembrolizumab: 5 of 5 rows · Tislelizumab: 3 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPembrolizumab
Rows use multiple source trials
Tislelizumab
EORTC QLQ-C30 GHS
absolute change · score
No placebo or comparator arm
-5.34 score @ 24wka,b,c
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
-3.44 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
3.3 score @ 15wka,b,c
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
2.4 score @ 15wk
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
n/a: no completion milestonePembrolizumabd
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
—Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
54%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
58.8%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
n/a: no completion milestonePembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
n/a: no completion milestone
NCT02775435 · Phase 3 · combination
n/a: no completion milestone
NCT02220894 · Phase 3
n/a: no completion milestone
NCT02504372 · Phase 3
89.3%200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
—Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
33%Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
0%Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
0%Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
—Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02864394 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT03850444 · Phase 3 · registry result, not featured evidence
2.5%
NCT03634241 · Phase 2 · registry result, not featured evidence
90.5%Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
60%Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
0%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
50%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
80.7%1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
89.2%2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
94.4%2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02955758 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
3.2%
NCT02733159 · Phase 2 · registry result, not featured evidence
87.7%
NCT03004183 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
86.4%
NCT03087760 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneTislelizumab + Nab-paclitaxel + Cae
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
n/a: no completion milestoneTislelizumab + Paclitaxel + Carbop
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
Discontinued due to AEs
8.4%Pembrolizumabd
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
—Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
4.9%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
6.7%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
11.5%
NCT02775435 · Phase 3 · combination
19.9%
NCT02220894 · Phase 3
—
NCT02504372 · Phase 3
—200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
—Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
—Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
—Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
3.1%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
—
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
—
NCT02864394 · Phase 3 · registry result, not featured evidence
12.5%
NCT03850444 · Phase 3 · registry result, not featured evidence
—
NCT03634241 · Phase 2 · registry result, not featured evidence
—Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
—Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
—800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
—Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
—Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
—1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—
NCT02955758 · Phase 2 · registry result, not featured evidence
—Pembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02733159 · Phase 2 · registry result, not featured evidence
12.3%
NCT03004183 · Phase 2 · registry result, not featured evidence
11.6%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
—
NCT03087760 · Phase 2 · registry result, not featured evidence
—Tislelizumab + Nab-paclitaxel + Cae
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
—Tislelizumab + Paclitaxel + Carbop
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
Serious AEs
—Pembrolizumabd
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
51.3%Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
16.7%Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
38.8%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
36.6%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
57.5%Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
22.2%Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
46%
NCT02775435 · Phase 3 · combination
41%
NCT02220894 · Phase 3
24.5%
NCT02504372 · Phase 3
20.7%200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
35%Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
37.7%Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
0%Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
7.7%Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
23.4%Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
50%Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
100%Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
54.7%Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
35.1%
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
53.8%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
36%
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
36.2%
NCT02864394 · Phase 3 · registry result, not featured evidence
32.8%
NCT03850444 · Phase 3 · registry result, not featured evidence
7.5%
NCT03634241 · Phase 2 · registry result, not featured evidence
9.5%Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
20%Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
60.8%800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
46.7%200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
52.5%Pembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
47.6%Pembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
37.8%
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
10.8%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
20%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
47.4%1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
54.1%2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
25%2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
36%
NCT02955758 · Phase 2 · registry result, not featured evidence
58.9%Pembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
45.1%Pembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
85%
NCT02733159 · Phase 2 · registry result, not featured evidence
51.8%
NCT03004183 · Phase 2 · registry result, not featured evidence
40.6%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
45.5%
NCT03087760 · Phase 2 · registry result, not featured evidence
46.6%Tislelizumab + Nab-paclitaxel + Cae
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
46.7%Tislelizumab + Paclitaxel + Carbop
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
Most frequent reported AEs
d
diarrhoea 26.6%
dyspnoea 26.6%
fatigue 24%
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 42 more results
upper respiratory tract infection 33.3%
constipation 16.7%
decreased appetite 16.7%
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
10 mg/kg
fatigue 25.7%
decreased appetite 23.3%
dyspnoea 23%
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
2 mg/kg
decreased appetite 30.7%
fatigue 30.1%
nausea 25.7%
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
nausea 57.3% (placebo 51%)
anaemia 45.9% (placebo 45%)
fatigue 42.7% (placebo 39.6%)
NCT02578680 · Phase 3 · combination
abdominal pain 22.2% (placebo 6.4%)
cough 22.2% (placebo 30.7%)
diarrhoea 22.2% (placebo 20.3%)
NCT02578680 · Phase 3 · combination
anaemia 53.2% (placebo 49.6%)
alopecia 46% (placebo 37.5%)
nausea 36.3% (placebo 32.1%)
NCT02775435 · Phase 3 · combination
decreased appetite 17%
cough 16.8%
dyspnoea 16.5%
NCT02220894 · Phase 3
weight increased 22.8% (placebo 28.9%)
pruritus 21.6% (placebo 12.7%)
hypothyroidism 20.7% (placebo 4.6%)
NCT02504372 · Phase 3
200 mg IV Q3W
hypothyroidism 17.3%
anaemia 12.7%
constipation 11.3%
NCT03715205 · Phase 4 · registry result, not featured evidence
anaemia 36.2%
nausea 24%
fatigue 17.2%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 37.7%
nausea 19%
aspartate aminotransferase increased 16.6%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 14.3%
covid-19 14.3%
headache 14.3%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 15.4%
cough 15.4%
productive cough 15.4%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 38.4%
nausea 30.9%
neutropenia 23.4%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anemia 75%
cough 75%
abdominal pain 50%
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
alanine aminotransferase increased 100%
alkaline phosphatase increased 100%
aspartate aminotransferase increased 100%
NCT03867175 · Phase 3 · registry result, not featured evidence
hypertension 41.4%
diarrhoea 40.9%
hypothyroidism 35.4%
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
anaemia 40.4% (placebo 44.7%)
nausea 39.2% (placebo 43.5%)
neutrophil count decreased 36.7% (placebo 45.9%)
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
alopecia 78.5%
white blood cell count decreased 78.5%
neutrophil count decreased 76.9%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
nausea 72% (placebo 53.3%)
constipation 64% (placebo 73.3%)
decreased appetite 56% (placebo 60%)
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
anaemia 33.3%
aspartate aminotransferase increased 21.6%
cough 21.6%
NCT02864394 · Phase 3 · registry result, not featured evidence
anaemia 30.5%
cough 23.4%
pyrexia 22.7%
NCT03850444 · Phase 3 · registry result, not featured evidence
fatigue 45%
investigations 25%
alanine aminotransferase increased 20%
NCT03634241 · Phase 2 · registry result, not featured evidence
anaemia 42.9%
diarrhoea 33.3%
fatigue 28.6%
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
asthenia 40%
blood creatinine increased 40%
blood urea increased 40%
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
800 mg
diarrhoea 29.4%
fatigue 21.6%
alanine aminotransferase increased 19.6%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
200 mg
pyrexia 23.3%
constipation 20%
decreased appetite 20%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
hypertension 52.5%
diarrhoea 45%
hypothyroidism 36.3%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
pruritus 29.3%
cough 22%
fatigue 20.7%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
fatigue 29.7%
pruritus 29.7%
nausea 24.3%
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
headache 40.5%
fatigue 24.3%
rash 21.6%
NCT02681549 · Phase 2 · registry result, not featured evidence
anorexia 40%
gastrointestinal disorders - other, specify 40%
hypertension 40%
NCT02681549 · Phase 2 · registry result, not featured evidence
asthenia 34.2%
dyspnoea 34.2%
cough 29.8%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
asthenia 21.6%
anaemia 18.9%
cough 18.9%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
decreased appetite 36.1%
dyspnoea 36.1%
cough 30.6%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
nausea 24%
decreased appetite 20%
worsening abdominal pain 20%
NCT02955758 · Phase 2 · registry result, not featured evidence
anaemia 39.3%
fatigue 34.8%
alopecia 31.3%
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
nausea 52%
asthenia 40.2%
anaemia 32.4%
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
fatigue 60%
dyspnea 48.3%
cough 35%
NCT02733159 · Phase 2 · registry result, not featured evidence
fatigue 21.4%
nausea 12.5%
back pain 10.7%
NCT03004183 · Phase 2 · registry result, not featured evidence
fatigue 56.5%
hypoalbuminemia 44.9%
hyponatremia 39.1%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
esophagitis 36.4%
fatigue 36.4%
hypothyroidism 22.7%
NCT03087760 · Phase 2 · registry result, not featured evidence
e
anaemia 94.1%
alopecia 69.5%
neutrophil count decreased 61.9%
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
anaemia 89.2%
alopecia 65%
neutrophil count decreased 65%
NCT03594747 · Phase 3 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cAssessment timepoints differ: 24 weeks versus 15 weeks.
  4. dPopulation comparability has not been reviewed for 42 of these studies.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pembrolizumab

PFS Rate at 6 62.1% (n=154) vs 50.3% (n=151) SOC Chemotherapy @ 24wk
responder rate · % of participants
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
OS Rate at 12 70.3% (n=154) vs 54.8% (n=151) SOC Chemotherapy @ 48wk
responder rate · % of participants
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Overall Survival 12.7 vs 8.5 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
10.4 vs 8.5 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
PFS 4 vs 4 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
3.9 vs 4 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
ORR 18.5% (n=346) vs 9.3% (n=343) Docetaxel10 mg/kg
responder rate · % of participants
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
18% (n=344) vs 9.3% (n=343) Docetaxel2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
Duration of Response NA vs 6.23 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
NA vs 6.23 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
Disease-free Survival 53.8 vs 43 placebo months
time to event · months
NCT02504372 · Phase 3
show 3 more results
67 vs 47.6 placebo months
NCT02504372 · Phase 3
58.7 vs 42.8 placebo months
NCT02504372 · Phase 3
53.6 vs 42 placebo months @ 295wk
NCT02504372 · Phase 3
PFS 7.1 months
time to event · months
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 7 more results
8.3 months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
7 months
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
2.6 months
NCT02955758 · Phase 2 · registry result, not featured evidence
29 months
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
45.3 months
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
4.39 months
NCT02733159 · Phase 2 · registry result, not featured evidence
Overall Survival 20.7 months
time to event · months
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 8 more results
23 months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT03634241 · Phase 2 · registry result, not featured evidence
22.3 months
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
13.3 months
NCT02955758 · Phase 2 · registry result, not featured evidence
35.6 months
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
56.7 months
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
9.8 months
NCT02733159 · Phase 2 · registry result, not featured evidence
Time to Deterioration Global Health Status 19.81 months
time to event · months
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
17.28 months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-LC13 -1.98 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
-1.82 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
-0.82 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
-0.47 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
Time to Deterioration QLQ-LC13 NA months
time to event · months
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
NA months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination

+ 43 further endpoints in the CSV export.

Tislelizumab

EORTC QLQ-LC13 Chest Pain 0.4 score @ 15wk
absolute change · score
No placebo or comparator arm
Chest pain
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-0.4 score @ 15wk
Chest pain
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ LC13 Cough -7 score @ 15wk
absolute change · score
No placebo or comparator arm
Coughing
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-0.4 score @ 15wk
Coughing
NCT03594747 · Phase 3 · registry result, not featured evidence · combination

Gastric Cancer

Shared mechanism: PD-1 · full Gastric Cancer pipeline

Pembrolizumab

Marketed by Merck & Co.

Approved in Gastric Cancermonoclonal antibody
Reliable signal

NCT03615326 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled phase 3 trial; 698 participants were randomized in its main cohort, more than the approximately 692 its published sample-size calculation required. Both primary endpoints were met: progression-free survival by blinded central review (hazard ratio 0.73) and overall survival (hazard ratio 0.80) were significantly better with pembrolizumab.

Next expected readout: December 2026 · NCT05041153 (registry estimate)

No aligned efficacy figure on record for this race.

Tislelizumab

Marketed by BeOne Medicines and partners

Approved in Gastric Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT05238883 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Gastric Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Tislelizumab: registry results are on file for Gastric Cancer, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pembrolizumab

Disease Control 47.6% (n=21)2.2 µg/kg
responder rate · % of participants
No placebo or comparator arm
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
show 11 more results
71.4% (n=14)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
47.6% (n=21)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
78.6% (n=14)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
51.6% (n=31)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
77.4% (n=31)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
53.5% (n=99)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
52.4% (n=105)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
56.7% (n=30)
NCT03797326 · Phase 2 · registry result, not featured evidence
57.4% (n=101)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
64.7% (n=102)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
37.9% (n=103)
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 12.4 months100 mg
time to event · months
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 14 more results
NA months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
NA months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
8.5 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
2.8 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
8.5 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
2.8 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
22.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
15.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT03797326 · Phase 2 · registry result, not featured evidence
4.6 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
6.2 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
5.8 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
PFS 2.1 months100 mg
time to event · months
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 15 more results
3 months100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.6 months75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
2.1 months50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
1.4 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
4.2 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
1.4 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
4.2 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
4.2 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
6.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.5 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
3.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence
3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
2.1 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
Overall Survival 4.4 months2.2 µg/kg
time to event · months
No placebo or comparator arm
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
show 9 more results
12.9 months2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
11.4 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
21.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.7 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
8.7 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
7.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence
8.6 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
7.9 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
4.3 months
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
ORR 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 5 more results
11% (n=118)100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
9.5% (n=21)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
28.6% (n=14)2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
Complete 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
1.7% (n=118)100 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0% (n=13)75 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0% (n=10)50 mg
Complete Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Partial 0% (n=10)100 mg
responder rate · % of participants
No placebo or comparator arm
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
show 3 more results
9.3% (n=118)100 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
7.7% (n=13)75 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
10% (n=10)50 mg
Partial Response
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
Available safety results

Pembrolizumab

Dropout rate
n/a: no completion milestoneCohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 27 more results
n/a: no completion milestoneCohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneCohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
25%Experimental: Expansion 1
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
0%Experimental: Expansion 2
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
4.8%Experimental: Expansion 3
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
0%Experimental: Safety Lead In
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—Cohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 27 more results
—Cohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
—Cohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Cohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
—Experimental: Expansion 1
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—Experimental: Expansion 2
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—Experimental: Expansion 3
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—Experimental: Safety Lead In
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
1.6%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
0%2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
50%2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
66.7%1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
0%1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
51.6%Cohort A: Triple Negative Breast C
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 27 more results
61.3%Cohort B: Ovarian Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
57.6%Cohort C: Gastric Cancer (Lenva +
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
52.4%Cohort D1: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
40%Cohort D2: Colorectal Cancer (Lenv
NCT03797326 · Phase 2 · registry result, not featured evidence
29.7%Cohort E: Glioblastoma Multiforma
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
60.8%Cohort F: Biliary Tract Cancer (Le
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
47.6%Cohort G: Pancreatic Cancer (Lenva
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
66.7%Experimental: Expansion 1
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
60%Experimental: Expansion 2
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
35%Experimental: Expansion 3
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
16.7%Experimental: Safety Lead In
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
45%300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
38.2%100 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
35.7%75 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
37.5%50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—2.2 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
—1.6 µg/kg
NCT02563548 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
hypertension 51.6%
diarrhoea 45.2%
hypothyroidism 45.2%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
show 19 more results
hypertension 67.7%
diarrhoea 61.3%
decreased appetite 48.4%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 37.4%
nausea 31.3%
asthenia 30.3%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.2%
diarrhoea 44.8%
decreased appetite 43.8%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.7%
diarrhoea 53.3%
dysphonia 40%
NCT03797326 · Phase 2 · registry result, not featured evidence
hypertension 50.5%
asthenia 28.7%
hypothyroidism 27.7%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 56.9%
diarrhoea 41.2%
fatigue 39.2%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
hypertension 53.4%
nausea 35.9%
decreased appetite 32%
NCT03797326 · Phase 2 · registry result, not featured evidence · combination
decreased appetite 50%
alanine aminotransferase increased 33.3%
diarrhea 33.3%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
anaemia 80%
dizziness 80%
fatigue 80%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
dizziness 45%
decreased appetite 30%
dyspnea 30%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
abdominal pain 66.7%
blood alkaline phosphatase increased 66.7%
fatigue 66.7%
NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination
300 mg BID + 200 mg Q3W
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg
diarrhoea 25.2%
constipation 23.6%
fatigue 23.6%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
75 mg
aspartate aminotransferase increased 21.4%
back pain 21.4%
fatigue 21.4%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination
50 mg
fatigue 37.5%
diarrhoea 25%
decreased appetite 18.8%
NCT02903914 · Phase 1 · registry result, not featured evidence · combination

Esophageal Squamous Cell Carcinoma

Shared mechanism: PD-1 · full Esophageal Squamous Cell Carcinoma pipeline

Pembrolizumab

Marketed by Merck & Co.

Approved in Esophageal Squamous Cell Carcinomamonoclonal antibody
Partial signal

NCT03189719 · Phase 3 · completed

KEYNOTE-590 was a randomized, double-blind, placebo-controlled Phase 3 in 749 patients with advanced esophageal or gastroesophageal junction carcinoma. Its primary endpoints, overall and progression-free survival, are clinical outcomes and were met. The benefit was concentrated in PD-L1 CPS >=1 tumours, and the sources read give no power calculation, so the grade is moderate.

Next expected readout: December 2026 · NCT06907602 (registry estimate)

Reported efficacy

Overall Survival (OS) in Participants With Esophageal Squamous Cell Carcinoma (ESCC) Whose Tumors Are Programmed Cell Death-Ligand 1 (PD-L1) Biomarker-Positive (Combined Positive Score [CPS] ≥10) (Up to approximately 34 months); OS in Participants With ESCC (Up to approximately 34 months); OS in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) (Up to approximately 34 months); OS in All Participants (Up to approximately 34 months); Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) As Assessed By Investigator in Participants With ESCC (Up to approximately 34 months); PFS Per RECIST 1.1 As Assessed By Investigator in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) (Up to approximately 34 months); PFS Per RECIST 1.1 As Assessed By Investigator in All Participants (Up to approximately 34 months): Primary endpoints, overall survival and progression-free survival: pembrolizumab plus cisplatin/fluorouracil improved both vs placebo plus chemotherapy; the label restricts use to PD-L1 CPS >=1, as an exploratory CPS <1 analysis showed OS HR 0.96 (KEYTRUDA label, KEYNOTE-590). (met)

Result source: NCT03189719

Tislelizumab

Marketed by BeOne Medicines and partners

Approved in Esophageal Squamous Cell Carcinomamonoclonal antibody
Partial signal

NCT03957590 · Phase 3 · completed

The study was randomized, quadruple-blind, placebo-controlled, and included 370 participants, with progression-free survival as a clinical primary endpoint. The primary comparison was not met: median progression-free survival was 29.0 versus 28.9 months, with a hazard ratio of 0.92 (95% CI 0.68–1.25; p=0.3016), so the evidence supports a well-designed but inconclusive or negative result rather than strong evidence of benefit.

Next expected readout: March 2027 · NCT07531979 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Tislelizumab + Chemoradiotherapy 29 months | Placebo + Chemoradiotherapy 28.9 months (missed)

Result source: NCT03957590

Results for Esophageal Squamous Cell Carcinoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Pembrolizumab
Primary endpoints, overall survival and progression-free survival: pembrolizumab plus cisplatin/fluorouracil improved both vs placebo plus chemotherapy; the label restricts use to PD-L1 CPS >=1, as an exploratory CPS <1 analysis showed OS HR 0.96 (KEYTRUDA label, KEYNOTE-590). NCT03189719 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Overall survival, pembrolizumab vs investigator's-choice chemotherapy: HR 0.70 (95% CI 0.52 to 0.94) in PD-L1 CPS >=10, HR 0.77 (0.63 to 0.96) in ESCC, HR 0.89 (0.75 to 1.05) in all randomized patients; the label approval is for ESCC with CPS >=10 (KEYTRUDA label, KEYNOTE-181). NCT02564263 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Tislelizumab
Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Tislelizumab + Chemoradiotherapy 29 months | Placebo + Chemoradiotherapy 28.9 months NCT03957590 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pembrolizumab's landscape · Tislelizumab's landscape